S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NYSE:ABBV

AbbVie - ABBV Stock Forecast, Price & News

$141.29
-0.15 (-0.11%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$139.82
$141.58
50-Day Range
$137.62
$154.14
52-Week Range
$105.56
$175.91
Volume
3.26 million shs
Average Volume
7.14 million shs
Market Capitalization
$249.81 billion
P/E Ratio
20.01
Dividend Yield
3.99%
Price Target
$159.63

AbbVie MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
13.0% Upside
$159.63 Price Target
Short Interest
Healthy
0.79% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.38mentions of AbbVie in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$12.04 M Sold Last Quarter
Proj. Earnings Growth
-16.01%
From $14.05 to $11.80 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

130th out of 1,119 stocks

Pharmaceutical Preparations Industry

45th out of 549 stocks

ABBV stock logo

About AbbVie (NYSE:ABBV) Stock

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Stock Down 0.8 %

Shares of NYSE:ABBV opened at $141.44 on Thursday. The company has a current ratio of 0.84, a quick ratio of 0.75 and a debt-to-equity ratio of 4.15. The stock has a fifty day simple moving average of $146.52 and a two-hundred day simple moving average of $150.47. AbbVie has a 12-month low of $105.56 and a 12-month high of $175.91. The stock has a market capitalization of $250.08 billion, a price-to-earnings ratio of 20.03, a PEG ratio of 3.99 and a beta of 0.70.

AbbVie (NYSE:ABBV - Get Rating) last posted its quarterly earnings results on Friday, July 29th. The company reported $3.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.42 by $0.09. AbbVie had a return on equity of 158.41% and a net margin of 22.03%. The firm had revenue of $14.58 billion during the quarter, compared to analyst estimates of $14.64 billion. During the same quarter in the previous year, the firm earned $3.11 EPS. AbbVie's quarterly revenue was up 4.5% compared to the same quarter last year. On average, research analysts anticipate that AbbVie will post 14.05 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 15th. Stockholders of record on Friday, July 15th were issued a dividend of $1.41 per share. This represents a $5.64 dividend on an annualized basis and a dividend yield of 3.99%. The ex-dividend date of this dividend was Thursday, July 14th. AbbVie's payout ratio is 79.89%.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of research analyst reports. Wells Fargo & Company boosted their price target on AbbVie from $165.00 to $200.00 in a report on Monday, May 2nd. Barclays decreased their target price on AbbVie to $160.00 in a report on Tuesday, August 9th. SVB Leerink initiated coverage on shares of AbbVie in a report on Monday, May 23rd. They issued an "underperform" rating and a $140.00 price target on the stock. Piper Sandler decreased their price objective on shares of AbbVie from $160.00 to $155.00 in a report on Friday, July 29th. Finally, UBS Group cut their target price on shares of AbbVie from $154.00 to $146.00 and set a "neutral" rating on the stock in a research note on Monday, August 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, AbbVie has an average rating of "Moderate Buy" and an average price target of $159.63.

Insider Activity at AbbVie

In other AbbVie news, Vice Chairman Michael Severino sold 79,801 shares of the stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $150.90, for a total transaction of $12,041,970.90. Following the sale, the insider now directly owns 152,103 shares in the company, valued at approximately $22,952,342.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.08% of the stock is owned by insiders.

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Stock News Headlines

Are Medtronic And Intuitive Surgical Poised For Big Growth? (ABBV)
Health care is one of the better-performing sectors in 2022, with medical gear makers Medtronic and Intuitive Surgical outpacing the broader industry recently.
Two Appealing Biotech Stocks for Two Distinct investors (ABBV)
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
3 Pharma Stocks' Post-Earnings Price Moves
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
MarketBeat: Week in Review 7/25 – 7/29 (ABBV)
The markets are rallying as big tech earnings are lifting investors' spirits. Here are some of the stocks our analysts were looking at this week.
Should You Buy AbbVie Ahead Of Earnings?
AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment?
MarketBeat: Week in Review 7/18 – 7/22 (ABBV)
Investors should be careful not to read too much into this week's rally. Next week will bring the Fed's decision on interest rates and key earnings reports from the tech sector. Both could cause significant movement in either direction. While you wait, here are some of the stocks our analysts were looking at this week
A Dose of AbbVie Stock Can Help Your Bear Market Portfolio
AbbVie (NYSE: ABBV) is a conventional stock for unconventional times. And that’s exactly why it makes sense to add or hold in your bear market portfolio.
1 Stock You Shouldn't Sell No Matter What
Top Analyst Reports for JPMorgan Chase, AbbVie & Abbott
This Analyst Cuts I-Mab's Price Target By 43%
5 Income Stocks to Turn to When Times Are Tough
AbbVie: Still A Solid Buy After Modeling Sales To 2030
AbbVie (NYSE:ABBV) Price Target Lowered to $160.00 at Barclays
Want Passive Income? Try These 3 Dividend Stocks
4 "Strong Buy" Stocks for a Fear-Driven Market
What's Happening With AbbVie Stock?
See More Headlines
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Company Calendar

Ex-Dividend for 8/15 Dividend
7/14/2022
Last Earnings
7/29/2022
Dividend Payable
8/15/2022
Today
8/18/2022
Next Earnings (Estimated)
11/04/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
00287Y10
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$159.63
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$135.00
Forecasted Upside/Downside
+13.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
16 Analysts

Profitability

Net Income
$11.54 billion
Pretax Margin
24.54%

Debt

Sales & Book Value

Annual Sales
$56.20 billion
Cash Flow
$17.51 per share
Book Value
$8.31 per share

Miscellaneous

Outstanding Shares
1,768,097,000
Free Float
1,766,683,000
Market Cap
$249.81 billion
Optionable
Optionable
Beta
0.70

Social Links


Key Executives

  • Mr. Richard A. GonzalezMr. Richard A. Gonzalez (Age 68)
    Chairman & CEO
    Comp: $7.42M
  • Mr. Robert A. MichaelMr. Robert A. Michael (Age 52)
    Vice Chairman & Pres
    Comp: $3.82M
  • Ms. Laura J. SchumacherMs. Laura J. Schumacher (Age 59)
    Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.
    Comp: $4.18M
  • Mr. Jeffrey Ryan StewartMr. Jeffrey Ryan Stewart (Age 53)
    Exec. VP & Chief Commercial Officer
    Comp: $3.25M
  • Mr. Scott T. ReentsMr. Scott T. Reents (Age 55)
    Sr. VP & CFO
  • Dr. Azita  Saleki-Gerhardt Ph.D.Dr. Azita Saleki-Gerhardt Ph.D. (Age 59)
    Exec. VP of Operations
  • Dr. Thomas J. Hudson (Age 60)
    Sr. VP of R&D and Chief Scientific Officer
  • Ms. Elizabeth Shea
    VP of Investor Relations
  • Mr. Timothy J. RichmondMr. Timothy J. Richmond (Age 56)
    Exec. VP & Chief HR Officer
  • Mr. Henry O. GosebruchMr. Henry O. Gosebruch (Age 49)
    Exec. VP & Chief Strategy Officer













ABBV Stock - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABBV shares.
View ABBV analyst ratings
or view top-rated stocks.

What is AbbVie's stock price forecast for 2022?

16 Wall Street analysts have issued 1-year target prices for AbbVie's shares. Their ABBV share price forecasts range from $135.00 to $200.00. On average, they expect the company's share price to reach $159.63 in the next twelve months. This suggests a possible upside of 13.0% from the stock's current price.
View analysts price targets for ABBV
or view top-rated stocks among Wall Street analysts.

How have ABBV shares performed in 2022?

AbbVie's stock was trading at $135.40 at the beginning of 2022. Since then, ABBV shares have increased by 4.4% and is now trading at $141.29.
View the best growth stocks for 2022 here
.

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our ABBV earnings forecast
.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings results on Friday, July, 29th. The company reported $3.51 EPS for the quarter, topping analysts' consensus estimates of $3.42 by $0.09. The company had revenue of $14.58 billion for the quarter, compared to analyst estimates of $14.64 billion. AbbVie had a trailing twelve-month return on equity of 158.41% and a net margin of 22.03%. AbbVie's revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company earned $3.11 EPS.
Read the conference call transcript
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Thursday, June 23rd. Investors of record on Friday, July 15th will be paid a dividend of $1.41 per share on Monday, August 15th. This represents a $5.64 dividend on an annualized basis and a dividend yield of 3.99%. The ex-dividend date is Thursday, July 14th.
Read our dividend analysis for ABBV
.

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $5.64 per share and currently has a dividend yield of 3.99%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 79.89%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 47.80% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its third quarter 2022 earnings guidance on Monday, August, 8th. The company provided earnings per share (EPS) guidance of $3.55-$3.59 for the period, compared to the consensus EPS estimate of $3.67. The company issued revenue guidance of $14.80 billion-$14.80 billion, compared to the consensus revenue estimate of $15.28 billion.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?
What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (4.36%), Price T Rowe Associates Inc. MD (1.74%), Northern Trust Corp (1.25%), FMR LLC (0.98%), Franklin Resources Inc. (0.73%) and UBS Asset Management Americas Inc. (0.62%). Insiders that own company stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and Timothy J Richmond.
View institutional ownership trends
.

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $141.29.

How much money does AbbVie make?

AbbVie (NYSE:ABBV) has a market capitalization of $249.81 billion and generates $56.20 billion in revenue each year. The company earns $11.54 billion in net income (profit) each year or $7.06 on an earnings per share basis.

How many employees does AbbVie have?

The company employs 50,000 workers across the globe.

Does AbbVie have any subsidiaries?
The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More
When was AbbVie founded?

AbbVie was founded in 2013.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.

This page (NYSE:ABBV) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.